|
|
EPIRUBICIN 50MG INJ (INP/AHI)
|
|
|
|
|
|
1000
|
|
|
ANTINEOPLASTICS
|
|
|
Acute leukaemias, lymphomas, solid tumours.
|
|
|
Leukopenia, nausea and vomiting, diarrhoea, thrombocytopenia, EKG changes, congestive cardiac failure secondary to a diffuse cardiomyopathy, alopecia. C.f. prescribing in liver disease p. 13.
|
|
|
|
|
|
|
|
|
Avoid during pregnancy. Teratogenic effects and embryotoxicity were noted in animal studies.
|
|
|
It is unknown whether epirubicin is distributed in milk. Breastfeeding is therefore not recommended due to the potential risks of adverse effects in the nursing infant.
|
|
|
|